CD30+ in Focus is a central hub for clinical data on the approved use of brentuximab vedotin (BV) a CD30-targeted monoclonal anti-body drug conjugate.
Hosted on Medscape, the leading global platform for physicians and healthcare professionals worldwide, CD30+ in focus offers a range of content suited to your learning style.
To access CD30+ in Focus, simply click the link below
CD30+ in Focus at a glance
Learn about BV and how it can improve the outcomes of patients with various lymphomas including:
- Hodgkin Lymphoma
- Cutaneous T-cell Lymphoma
- Systemic Anaplastic Large Cell Lymphoma